JAK inhibitors in myeloproliferative neoplasms: rationale, current data and perspective
{{output}}
JAK-STAT is an appealing but also problematic drug target in BCR-ABL1-negative myeloproliferative neoplasms (MPN) - it is appealing because the majority of patients with MPN harbor gain-of-function JAK2 or MPL mutations - it is problematic because currently av... ...
